Tadashi Matsushita

Professor
Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan.

Presentation(s):

• LB 01.1 - A Phase 3 study (ATLAS-PPX) to evaluate efficacy and safety of fitusiran, an siRNA therapeutic, in people with haemophilia A or B who have switched from prior factor or bypassing agent prophylaxis

  Sunday, July 10, 2022
  2:45 PM – 3:00 PM

• LB 01.2 - Concizumab Prophylaxis in Patients With Haemophilia A or B With Inhibitors: Efficacy and Safety Results From the Primary Analysis of the Phase 3 explorer7 Trial

  Sunday, July 10, 2022
  3:00 PM – 3:15 PM

• VPB0693 - First year report of the multicenter prospective cohort study on ischemic events in adult patients with hemophilia (ADVANCE Japan)

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB1123 - Annualised Bleeding Rate and Joint Health: Second Interim Analysis of the Real-world HEM-POWR Study Evaluating the Effectiveness of Damoctocog Alfa Pegol in Patients With Haemophilia A

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM